Evidence map›Paper›PMID 40104506›Full record

ArticleFrontiers in oncology2025

Radiation hematologic toxicity prediction in rectal cancer: a comparative radiomics-based study on CT image and dose map.

Yingpeng Liu, Liping Guo, Yi Wang, Qingtao Xu, Jingfeng Zhang, Xianyun Meng

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yingpeng Liu *Department of Radiology, Ningbo No. 2 Hospital, Ningbo, China.
Liping Guo *Department of Radiology, Ningbo No. 2 Hospital, Ningbo, China.
Yi WangDepartment of Radiotherapy and Chemotherapy, Ningbo No. 2 Hospital, Ningbo, China.
Qingtao XuCancer Radiochemotherapy Center, First Affiliated Hospital of Ningbo University, Ningbo, China.
Jingfeng ZhangDepartment of Radiology, Ningbo No. 2 Hospital, Ningbo, China.
Xianyun MengDepartment of Radiology, Ningbo No. 2 Hospital, Ningbo, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and objectives: Acute radiation hematologic toxicity may disturb the radiotherapy plan and thus decrease the treatment outcome. However, whether the dose map has enough prediction value for detecting hematologic toxicity (HT) is still unknown. Methods: In this study, the pre-treatment CT images and the in-treatment dose map were collected from a discovery dataset of 299 patients and a validation dataset of 65 patients from another center. Then, the radiomic features of the clinical target volume (CTV) in the radiotherapy were extracted, and the least absolute shrinkage and selection operator (LASSO) algorithm was used for feature dimension deduction; three classifiers, that is, support vector machine (SVM) (rbf kernel), random forest, and CatBoost, were used to construct the HT classification model in rectal cancer patients. The model performance was evaluated by both the internal 20% dataset and the external multicenter dataset. Results: The results revealed that CatBoost achieved the best model performance in almost all tasks and that CT images performed similarly with the dose map, although their combination model performed lower. In addition, gender, age, and some radiomic features from the decomposed image space were the most representative features for HT prediction. Conclusion: Our study can confirm that the HT occurrence in locally advanced rectal cancer (LARC) patients was multifactorial, and combining effective features together can classify the high-risk patients with HT, thus timely preventing or detecting HT to improve the subsequent outcome.

Indexed as

CatBoostdose mapradiation hematologic toxicityradiomicsrectal cancer

Identifiers

PMID40104506
PMCPMC11913847

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.